Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes.

导出 LinkOut

翻译打印收藏纠错

作者： Lucia,Brodosi ^[1] ; Maria Letizia,Petroni ^[1] ; Giulio,Marchesini ^[2]

作者单位： Unit of Clinical Nutrition and Metabolism, IRCCS-Azienda Ospedaliera di Bologna Sant'Orsola-Malpighi, Bologna, Italy. ^[1] Department of Medical and Surgical Sciences, Alma Mater University of Bologna, Bologna, Italy. ^[2]

关键词 Amylin receptor cholecystokinin receptor 2 cirrhosis cirrhosis, glucagon receptor fibroblast growth factor 21 glucagon-like peptide 1 glucagon-like peptide 2 glucose-dependent insulinotropic peptide

主题词动物(Animals);人类(Humans);肠促胰岛素类(Incretins);糖尿病, 2型(Diabetes Mellitus, Type 2);胰高血糖素样肽1(Glucagon-Like Peptide 1)

DOI 10.1080/14656566.2023.2208746

PMID 37114459

发布时间 2023-05-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Expert opinion on pharmacotherapy

2023年24卷9期

989-1000页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes.

Expert opinion on pharmacotherapy

相似文献

Expert opinion on pharmacotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes.

Expert opinion on pharmacotherapy

相似文献

Expert opinion on pharmacotherapy

相关期刊

检索历史清除